INmuneBio sets IPO terms

INmuneBio Inc. (La Jolla, Calif.) amended its NASDAQ IPO and now plans to sell between 1 million and 2.5 million shares at $8. At the midpoint of 1.75 million shares, the company would raise $14 million and be valued at $83.8 million based on 10.5 million shares outstanding. Univest, WallachBeth and WestPark are underwriting the offering.

INmuneBio has two products in development, INKmune and INB03. INKmune is a natural killer (NK) cell therapeutic in Phase I/II testing to treat high-risk ovarian cancer and high-risk myelodysplastic syndrome (MDS). INB03 is an immune checkpoint inhibitor targeting myelogenous derived suppressor cells; the therapy is in Phase I testing. ...